⚡ Interrogation des APIs scientifiques en cours…
⚡ Interrogation des APIs scientifiques en cours…
Authors' conclusion
Does not affect the score
Publi-Score
Fidelity
Abstract (PubMed)
BACKGROUND: Viral epidemics or pandemics of acute respiratory infections (ARIs) pose a global threat. Examples are influenza (H1N1) caused by the H1N1pdm09 virus in 2009, severe acute respiratory syndrome (SARS) in 2003, and coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in 2019. Antiviral drugs and vaccines may be insufficient to prevent their spread. This is an update of a Cochrane Review last published in 2020. We include results from studies from the current COVID-19 pandemic. OBJECTIVES: To assess the effectiveness of physical interventions to interrupt or reduce the spread of acute respiratory infections. SEARCH METHODS: We searched CENTRAL, PubMed, Embase and CINAHL from the inception of each database to 1 April 2022. MAIN RESULTS: We included 78 randomised trials (RCTs) with 610,872 participants. Medical/surgical masks compared to no masks probably makes little or no difference to the outcome of influenza-like illness (ILI) compared to no masks (RR 1.01, 95% CI 0.72 to 1.42; 9 RCTs; n=3507). N95/P2 respirators compared to medical/surgical masks makes little or no difference to the outcome of ILI (RR 1.06, 95% CI 0.90 to 1.25; 11 RCTs; n=28,746). Hand hygiene compared to control probably makes little or no difference to the outcome of COVID-19 (RR 0.86, 95% CI 0.60 to 1.23; low certainty evidence). CONCLUSIONS: The high risk of bias in the trials, variation in outcome measurement, and relatively low adherence with the interventions during the studies hampers drawing firm conclusions.
Coeff. authors = avg(0.85, 1.00) = 0.93
Coeff. editorial = avg(0.90, 0.90) = 0.90
min(0.93, 0.90) = 0.90← lowest dominates
Final coefficient : 0.90
Final score = 50.8/100 × 0.90 × 100 = 46/100
Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring …
Azzolini E — 2022 · JAMA
Contrasted resultsMeta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection
Hill A — 2021 · Open Forum Infectious Diseases
Contrasted resultsAdverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: A …
Amanzio M — 2022 · Lancet Reg Health Eur
Contrasted resultsIvermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Met…
Bryant A — 2021 · American journal of therapeutics
Contrasted resultsNeutralizing antibody levels are highly predictive of immune protection from symptomati…
Khoury DS — 2021 · Nature medicine